Clinical Trial Update: Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

The Phase 2 study evaluating the combination of Iressa (gefitinib) and Anastrozole (Arimidex) in ovarian, peritoneal, and tubal carcinomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Carcinoma
• Tubal Carcinoma

Drugs mentioned

• ARIMIDEX (anastrozole)
• Iressa (gefitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Ovarian Cancer, Peritoneal Carcinoma | Phase 2 | Status: COMPLETED